熱門資訊> 正文

Editas Medicine股价因拟议股权发行而下跌

2026-05-26 18:53

Editas Medicine, Inc.(EDIT) 0
富國銀行(WFC) 0

Editas Medicine (EDIT) shares fell nearly -12% premarket on Tuesday after the gene editing company launched an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants.
Cantor and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.

More on Editas Medicine

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Editas Medicine GAAP EPS of -$0.06 beats by $0.20, revenue of $24.74M beats by $15.97M
Seeking Alpha’s Quant Rating on Editas Medicine
Historical earnings data for Editas Medicine
Financial information for Editas Medicine

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。